Tiny white bumps on your face can be frustrating, but understanding their cause is key to effective treatment. Milia, closed ...

The company hopes to push the rare-disease treatment toward FDA approval next year. Four months after ditching its lead drug, ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ...

Needham analyst Ami Fadia upgraded Neurocrine (NBIX) to Buy from Hold with a $138 price target The firm cites its positive physician survey on ...